Stocks · Healthcare · Biotechnology
ADMA Biologics, Inc. ADMA
$9.72 -2.11% Close, Oct 2, 2026 · NASDAQ · Market cap $2.25B
High qualityInexpensive vs sector
Next earnings report: Nov 4, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin widened to 42.3% from 32.8% a year earlier.
- The shares trade at 13.9× trailing earnings, lower than 89% of the company's own readings over the past five years.
- The diluted share count fell 7.3% in a year, mainly through buybacks.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 47%
- EPS growth (TTM, YoY)Bottom 37%
- FCF growth (TTM, YoY)Top 20%
- Revenue growth, 3-year CAGRTop 14%
- Revenue growth accelerationBottom 32%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 3%
- Gross marginTop 50%
- Operating marginTop 3%
- Cash conversion (OCF / net income)Bottom 19%
- Accruals (lower is better)Bottom 10%
- Net debt / EBITDA (lower is better)Top 40%
- Interest coverTop 7%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 5%
- Free-cash-flow yieldTop 17%
- EBITDA / enterprise valueTop 9%
- Sales / enterprise valueTop 50%
- P/E vs own 5-year history (lower is better)Top 26%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 12%
- 6-month returnBottom 49%
- 1-year return vs S&P 500Bottom 18%
- Distance from 52-week highBottom 26%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 44%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 27%
- Upside to consensus price targetTop 39%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 24%
- Maximum drawdown, 3 yearsTop 49%
- Beta vs S&P 500 (lower is better)Top 32%
- Net debt / EBITDA (lower is better)Top 40%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 11.0% | 8.0% | ↓ |
| EPS growth (YoY) | -20.0% | -18.6% | ↑ |
| Gross margin | 53.0% | 64.7% | ↑ |
| Operating margin | 32.8% | 42.3% | ↑ |
| FCF margin | 13.9% | 22.7% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 8.0% | 11.0% | ↓ | Bottom 47% |
| EPS growth (TTM, YoY) | -18.6% | -20.0% | ↑ | Bottom 37% |
| Gross margin | 64.7% | 53.0% | ↑ | Top 50% |
| Operating margin | 42.3% | 32.8% | ↑ | Top 3% |
| Net margin | 33.0% | 44.1% | ↓ | — |
| Free-cash-flow margin | 22.7% | 13.9% | ↑ | — |
| Return on invested capital | 27.5% | — | Top 3% | |
| Revenue growth, 3-year CAGR | 49.0% | — | Top 14% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 0.81×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 4.7%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 4.5%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +17.9 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 0.29×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 24.5×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 8.24%
- Shareholder yield
- 8.24%
- Share count change, 1 year
- -7.3%
- Share count change, 3-year CAGR
- +1.1%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 5, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 3 of 8
- Average EPS surprise, last 4
- +1.1%
- Average 2-day reaction, last 8
- +0.6%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $18.67
- Target vs current price
- +92.1%
- Analysts with a rating
- 10
- Share rating Buy or Strong Buy
- 90%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 5, 2026 | -2.0% | +3.9% | +11.1% | +4.7% | — |
| May 6, 2026 | -1.7% | -1.7% | -18.0% | -24.3% | -17.5% |
| Feb 25, 2026 | +8.1% | +1.0% | +5.5% | -27.0% | -44.8% |
| Nov 5, 2025 | +0.0% | +5.1% | +9.6% | +34.8% | +19.6% |
| Aug 6, 2025 | +7.1% | -2.2% | -11.6% | -10.9% | -18.1% |
| May 7, 2025 | -12.5% | +2.1% | -14.0% | -12.1% | -16.4% |
| Mar 3, 2025 | -6.7% | -3.4% | +3.8% | +23.6% | +21.4% |
| Nov 7, 2024 | +15.4% | +0.3% | +9.2% | -1.8% | -14.2% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | $0.16 | $0.16 | -2.0% | $124.4M |
| May 6, 2026 | $0.19 | $0.19 | -1.7% | $114.5M |
| Feb 25, 2026 | $0.20 | $0.19 | +8.1% | $139.2M |
| Nov 5, 2025 | $0.16 | $0.16 | +0.0% | $134.2M |
| Aug 6, 2025 | $0.15 | $0.14 | +7.1% | $122.0M |
| May 7, 2025 | $0.14 | $0.16 | -12.5% | $114.8M |
| Mar 3, 2025 | $0.14 | $0.15 | -6.7% | $117.5M |
| Nov 7, 2024 | $0.15 | $0.13 | +15.4% | $119.8M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 13.9× | 22.9× | 11th | Top 5% |
| P/E (forward) | 12.2× | — | — | — |
| EV / EBITDA | 9.9× | — | — | Top 9% |
| EV / Sales | 4.53× | — | — | Top 50% |
| Free-cash-flow yield | 5.17% | — | — | Top 17% |
| Earnings yield | 7.20% | — | — | Top 5% |
P/E over the past five years
Range 13.2× – 88.2× since Jun 30, 2024. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- -35.4%
- Earnings per share growth (TTM)
- -18.6%
- Change in P/E multiple
- -38.6%
Most of the move came from a change in the valuation multiple.
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 10
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- +3.0%
- 200-day average slope (20 days)
- -7.3%
- Distance from 50-day average
- +3.4%
- Distance from 200-day average
- -17.3%
- RSI (14)
- 53.4
- Relative volume
- 0.89×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 41.2%
- Volatility vs own 5-year history
- 12th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.81
- Correlation with S&P 500
- 0.21
- Current drawdown from 1-year high
- -52.3%
- Maximum drawdown, 3 years
- -69.0%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Apr 28, 2025 | Jun 2, 2026 | -69.0% | 275 days | Not yet recovered |
| Feb 9, 2021 | Oct 11, 2021 | -63.0% | 169 days | 274 days (Nov 10, 2022) |
| Aug 14, 2023 | Oct 23, 2023 | -33.2% | 49 days | 52 days (Jan 8, 2024) |
| Nov 8, 2024 | Feb 25, 2025 | -31.7% | 71 days | 43 days (Apr 28, 2025) |
| Oct 7, 2020 | Nov 19, 2020 | -29.7% | 31 days | 50 days (Feb 3, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $2.25B
- P/E (TTM)
- 13.9
- EPS, diluted (TTM)
- $0.70
- Revenue (TTM)
- $512.3M
- 52-week range
- $7.21 – $20.46
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $80.9M | $154.1M | $258.2M | $426.5M | $510.2M |
| Gross profit | $1.2M | $35.3M | $88.9M | $219.6M | $292.8M |
| Operating income | -$58.4M | -$39.4M | $21.6M | $139.0M | $191.4M |
| Net income | -$71.6M | -$65.9M | -$28.2M | $197.7M | $146.9M |
| EPS (diluted) | -$0.61 | -$0.43 | -$0.13 | $0.81 | $0.60 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $119.8M | $117.5M | $114.8M | $122.0M | $134.2M | $139.2M | $114.5M | $124.4M |
| Net income | $35.9M | $111.9M | $26.9M | $34.2M | $36.4M | $49.4M | $45.3M | $37.8M |
| EPS (diluted) | $0.15 | $0.46 | $0.11 | $0.14 | $0.15 | $0.20 | $0.19 | $0.16 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$112.4M | -$59.5M | $8.8M | $118.7M | $50.4M |
| Capital expenditure | -$13.5M | -$13.9M | -$5.0M | -$8.6M | -$22.6M |
| Free cash flow | -$125.9M | -$73.4M | $3.8M | $110.1M | $27.8M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $121.1M | $64.6M | -$1.4M | $7.5M | -$29.0M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $136.0M
- Total assets
- $684.2M
- Total liabilities
- $276.0M
- Total debt
- $203.8M
- Net debt
- $67.8M
- Shareholders’ equity
- $408.2M
As of Jun 30, 2026 (filed Aug 5, 2026).
Short interest
- Shares sold short
- 24,206,749
- Days to cover
- 10.81
- Change vs previous report
- +1.4%
FINRA short interest, settlement date Sep 15, 2026.